Compensan retard

Quick links to important sections

Compensan retard

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Compensan retard

Quick Facts

Property Description
Active ingredient Morphine Sulfate
Form Prolonged-release tablet (Depottablett)
Pharmacological class Opioid Analgesic
General purpose Substitution and Maintenance Therapy
Origin Semi-synthetic Opioid

What Type of Medicine is Compensan retard? (Identity and Classification)

Compensan retard is a prescription-only pharmaceutical preparation with the active ingredient Morphine Sulfate, classified as a potent opioid analgesic medication intended for oral administration. It functions as a single-active-ingredient product.

The drug belongs to the pharmacological class of opioids. Morphine is recognized as a standard for strong pain relief. As an opioid pure agonist, the medication acts centrally on mu -opioid receptors to modulate pain signals, establishing its status as a controlled substance reserved for situations requiring specialized, potent systemic relief.

Composition, Form, and Origin

The characteristic feature of this medication is its unique dosage form, a prolonged-release tablet (Depottablett). The Morphine Sulfate it contains is derived from the natural alkaloid morphine, classifying the drug as a semi-synthetic opioid in composition.

This specific form employs a sustained-release matrix to physically control the rate at which the active substance is released and absorbed in the gastrointestinal tract. This deliberate design achieves a long duration of action and is a key differentiator from traditional immediate-release tablets. Extended-release morphine formulations are characterized by their ability to maintain steady plasma concentrations over 24 hours. This means the medication works consistently in the body throughout the entire day.

General Purpose as a Substitution Medicine

The general purpose of Compensan retard is to function as a substitution medicine for the maintenance therapy of opioid-dependent adults.

The medication's long duration of action is crucial to this role, as it ensures a stable and sustained level of the opioid analgesic throughout the day. The use of prolonged-release morphine for maintenance treatment involves stable patient populations requiring continuous opioid support. This sustained delivery mechanism is designed to provide the long-term stability required in maintenance therapy settings.

Regulatory References

  1. Morphine MedlinePlus Drug Information

What side effects are possible with Compensan retard?

Official Adverse Reactions and Safety Profile

The safety profile of prolonged-release morphine sulfate is formally categorized in regulatory documents, defining both common expected effects and major safety constraints.

Classification Representative Adverse Reactions
Very Common Nausea, Constipation, Somnolence (drowsiness), Vomiting, Sedation.
Common Dizziness, Headache, Dry mouth, Sweating, Pruritus (itching), Urinary retention, Mood changes.

These effects are typically grouped by the body system affected, with the most frequently observed reactions impacting the Gastrointestinal Disorders (e.g., constipation) and Nervous System Disorders (e.g., somnolence, dizziness) system-organ classes.

Serious Adverse Reactions and Key Constraints

Official labeling emphasizes several severe and potentially life-threatening risks associated with this class of medicine:

  • Life-Threatening Respiratory Depression: This is the primary hazard, which can occur, particularly during treatment initiation or following a dose increase. It is the most serious adverse event documented.
  • Addiction, Abuse, and Dependence: Prolonged use carries the risk of developing physical and psychological dependence and Opioid Use Disorder (OUD).
  • Neonatal Opioid Withdrawal Syndrome (NOWS): Use during pregnancy can result in this syndrome in the newborn.
  • Severe Constraints: The medicine is formally contraindicated in patients with significant respiratory depression, acute bronchial asthma, known or suspected paralytic ileus (bowel obstruction), and in those taking Monoamine Oxidase Inhibitors (MAOIs).

Population and Exposure-Related Safety Notes

The risk profile requires additional caution for certain groups. Older adults and debilitated patients are at an increased risk for respiratory depression. Patients with severe renal or hepatic impairment may experience slower clearance of the substance, necessitating close monitoring as stated in regulatory documents.

Adverse effects, such as nausea and vomiting, are often more common at the start of treatment, whereas the development of tolerance and dependence are consequences of repeated and long-term administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Regulatory Overdose Profile

An overdose of Compensan retard (Morphine) is a serious medical emergency. As a prolonged-release opioid, an overdose can result in delayed, prolonged, and severe toxicity. The clinical presentation of an acute overdose is primarily defined by its effects on the central nervous system (CNS) and respiratory system.

Documented Manifestations and Serious Outcomes

Official regulatory documents identify the critical signs of severe overdose, which include:

  • Profound Respiratory Depression: Slowed or shallow breathing, which may progress to the cessation of breathing (respiratory arrest).
  • CNS Depression: Extreme drowsiness (somnolence), progressing to stupor and eventually coma.
  • Pupil Changes: Severe miosis (pinpoint pupils).
  • Muscle Flaccidity: Loss of muscle tone.
  • Skin Changes: Cold and clammy skin.

The most serious and life-threatening consequence is respiratory failure leading to death.

Required Emergency Actions

Immediate medical attention is mandatory for any suspected overdose or if any signs of serious toxicity are observed, even if the person appears to feel well initially.

The immediate treatment dictated by regulatory standards involves establishing and maintaining a patent airway and providing assisted ventilation. The specific pharmacological treatment for severe respiratory depression caused by opioid overdose is the administration of an opioid antagonist, most commonly Naloxone, which may require repeat doses due to the prolonged-release nature of Compensan retard.

Therapeutic Uses of Compensan retard

What Compensan Retard Treats: Main Uses and Benefits

The prolonged-release formulation of Compensan retard is defined by its role in the pharmacological support of opioid-dependent adults, generally applied across therapeutic domains involving chronic physiological dependence. Extended-release morphine formulations may be used for opioid use disorder (OUD) in specific countries as an opiate substitution therapy (OST).

The medication is commonly used to help manage conditions such as opioid dependence and the need for opioid maintenance treatment. This medication is applied in clinical settings marked by increased discomfort or tension, such as the severe, persistent symptoms associated with this condition within a structured clinical setting. It supports the patient during difficult episodes by providing consistent pharmacological support to manage a persistent condition, which contributes to treatment retention and adherence to necessary comprehensive psychosocial care settings.

Compensan retard is relevant for easing symptom clusters that may become intense or disruptive, specifically addressing the profound discomfort of opioid withdrawal and the persistent, compulsive nature of opioid craving. It may assist in reducing the impulse associated with craving, which supports the reduction of illicit opioid use. The sustained-release design is designed to contribute to sustained stability, and generally helps to manage symptoms that may intensify temporarily, such as the daily fluctuation common in dependence.

“The sustained effect assists with maintaining functional stability and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Dependence Symptoms

Feature Therapeutic Benefit
Primary Indication Opioid Dependence (Maintenance Treatment)
Symptom Focus Opioid Withdrawal and Compulsive Craving
Key Benefit Sustained Symptom Stability (24-hour support)
Usage Context Integrated within Comprehensive Psychosocial Care

Regulatory References

  1. NIH MedlinePlus overview of Morphine

Eligibility and Restrictions for Use

Eligibility for Compensan retard

Compensan retard (morphine sulfate prolonged-release) is strictly intended for adults who require continuous, around-the-clock opioid support. Use of the higher-strength tablets is restricted to opioid-tolerant patients only. The safety and efficacy of this extended-release formulation have not been established in the pediatric population (children), and accidental ingestion of even a single dose by a child is an explicitly documented risk for fatal overdose.

Contraindicated (Must Not Use) Populations Restricted or Conditional Use Populations
Significant respiratory depression Severe hepatic impairment (use with caution)
Acute or severe bronchial asthma Severe renal impairment (use with caution)
Gastrointestinal obstruction or paralytic ileus Elderly or debilitated patients (monitor closely)
Monoamine Oxidase Inhibitors (MAOIs) use (concurrently or within 14 days) Increased intracranial pressure or head injury (avoid in coma)

Pregnancy and Lactation Status: Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Regulators do not recommend breastfeeding due to morphine excretion in human milk and the risk of serious adverse reactions in the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official interaction constraints documented in government regulatory labeling for morphine sulfate.

Documented High-Risk Combinations

Classification Interacting Substances/Classes Regulatory Constraint
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Must not be used concurrently or within 14 days of the MAOI [Source 1.6].
Avoid Use Mixed Agonist/Antagonist Opioids (e.g., Pentazocine, Nalbuphine) May reduce the therapeutic effect or precipitate withdrawal symptoms [Source 1.6].
High Risk CNS Depressants and Alcohol Additive pharmacodynamic effects may result in profound sedation, respiratory depression, coma, and death [Source 1.1].

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with other medicines can alter the effects of Compensan retard through two primary documented patterns:

  • Exposure Modification: Substances that inhibit P-glycoprotein (P-gp) may increase the systemic exposure of the medicine. Conversely, certain enzyme inducers, such as Rifampicin, are noted in the label to reduce plasma concentrations [Source 3.7].
  • Pharmacodynamic Reinforcement: Drugs that affect the serotonergic system may contribute to the risk of serotonin syndrome. Co-use with Skeletal Muscle Relaxants may enhance the risk of respiratory depression [Source 2.5].

Specialized caution is advised for elderly or debilitated patients due to the increased risk of severe respiratory depression when co-administered with other CNS depressants [Source 1.2].

Mechanism of Action

How Compensan Retard Works

Compensan Retard exerts its pharmacodynamic effects primarily through alpha-adrenergic receptor blockade. The medication acts as an antagonist on these receptors, which are located on the smooth muscle of peripheral blood vessels and within the central nervous system.

Blocking the alpha1-adrenergic receptors on vascular smooth muscle prevents the binding of endogenous vasoconstrictors, leading directly to vasodilation and a resultant decrease in peripheral vascular resistance.

Simultaneously, the drug modulates central pathways, interacting with specific receptors that influence outgoing nerve signals (sympathetic outflow). This action decreases sympathetic outflow, which further influences peripheral vascular resistance. The controlled-release ('retard') formulation maintains a consistent concentration to prolong the receptor blockade, thereby ensuring a continuous and predictable modulation of systemic vascular resistance.

Dosage and Administration Information

How to Use Compensan retard: Official Administration Guidelines

Compensan retard (Morphine Sulfate prolonged-release tablet) is administered according to established protocols to ensure the intended sustained action and stability, particularly when used for maintenance treatment of opioid dependence. The following details describe the standard administration parameters.


Administration and Dosing

The approved route of administration for this form is oral (swallowing). The tablets are designed to release the medicine slowly and must be swallowed whole; they must not be broken, crushed, chewed, or dissolved. Altering the tablet will result in the immediate release of the entire dose.

Dosing Principle Regulatory Instruction
Dosing Frequency Typically taken once daily or every 12 hours to maintain consistent levels.
Timing & Food Should be taken at the same time every day and may be taken with or without food.
Maintenance Dose Maintenance dosing is typically established by converting from a known, effective total daily dose of immediate-release morphine; dose increases are generally made in 30% to 50% increments if needed.

Procedural Conditions and Use Over Time

Treatment is undertaken within the context of appropriate medical monitoring and comprehensive psychosocial care.

Special Population Guidance:

  • Older Adults: A reduction in dosage may be advisable based on clinical assessment.
  • Renal/Hepatic Impairment: Treatment is generally not initiated with the prolonged-release form; stabilization typically occurs using an immediate-release form first.

The medicine should be used no longer than necessary. When discontinuing long-term treatment, the dose is gradually reduced or progressively lowered under supervision. Abrupt cessation is generally avoided.

Recent Clinical Evidence

Evidence for use in Opioid Maintenance Treatment

This section describes the types of clinical studies that have examined the prolonged-release formulation for its use in Opioid Dependence (Maintenance Treatment). The research explored this medication, which is a condition characterized by fluctuating or episodic manifestations, utilizing short-term Randomized Controlled Trials (RCTs) and systematic reviews.

Researchers monitored core functional outcomes, including treatment retention rates and measures of illicit opioid use. The research also explored this formulation alongside methadone in comparative studies. Findings describe patterns observed in the studies related to treatment retention and measured patterns concerning the frequency of illicit opioid use. Some trials described mixed patterns related to outcomes monitoring physiological strain or stress (withdrawal). Overall, evidence contributes to understanding symptom patterns.


Long-term Studies and Research Gaps

For a condition presenting with cycles of stability and flare-ups, many of the core comparative studies have limited follow-up durations. This means that long-term effects are not fully established by the high-quality randomized evidence. While some large observational studies describe follow-up lasting up to 1 to 2 years, the evidence base for long-term functional outcomes over multiple years remains limited across the available RCTs.

Scientific reviews data show patterns related to several limitations. Firstly, the core research relies on a limited number of RCTs with modest sample sizes. This means the evidence quality varies across studies, and the findings describe group patterns, not personal outcomes. Additionally, comparative evidence is lacking for certain opioid maintenance treatments.


Evidence in Special Populations

Data for certain groups remain insufficient. The existing research primarily focused on adults who were otherwise clinically stable. For instance, there is limited information regarding use in older adults, pregnant individuals, or patients with co-occurring chronic conditions. Therefore, the evidence quality varies across studies when attempting to generalize findings to these more specialized patient groups.

Key Studies & References

  1. Morphine Monograph and mechanism of action
  2. An open-label randomized trial of slow-release oral morphine versus methadone in the treatment of opioid dependence (Example RCT)

Frequently Asked Questions (FAQ)

Common questions about Compensan retard (FAQ)


Q: What is the main difference between Compensan retard and the non-retard version?

A: According to the official product information, the Compensan retard (prolonged-release) version is designed with a special matrix to release the medicine slowly over many hours. This sustained action typically allows for once or twice-daily dosing to maintain a stable level in the body. In contrast, the non-retard (immediate-release) form releases the medicine quickly, and it is usually administered every four to six hours.


Q: How quickly should I expect to notice anything after starting Compensan retard?

A: Regulatory documents do not detail individual onset of effect, focusing instead on sustained action and maintaining a consistent level of the substance over time. Official safety warnings indicate that close monitoring is crucial for serious risks, such as life-threatening breathing problems, which may occur during the first 24 to 72 hours of starting treatment.


Q: Can Compensan retard be taken with over-the-counter cold and flu medicine?

A: Official labeling describes constraints regarding use with other medications that affect the Central Nervous System (CNS), which can include ingredients found in some cold and flu medicines. Co-use with CNS depressants may increase the risk of profound sedation and serious respiratory depression (slow, shallow breathing).


Q: Is it common for the dose to be adjusted after the first few weeks?

A: Official guidelines indicate that dose adjustment is a standard component of the titration and maintenance process. The dose may be adjusted during the course of therapy based on the patient's response and any side effects experienced. The goal of adjustment is often to maintain the lowest level consistent with therapeutic needs.


Q: Does taking Compensan retard cause stomach upset?

A: Yes, official safety information lists nausea and vomiting as very common adverse reactions. These effects, along with constipation, are frequently reported, particularly when treatment is first initiated.


Q: Is it normal to feel nauseous when first taking Compensan retard?

A: Official documents explicitly note that adverse effects such as nausea and vomiting are often more common at the start of treatment with this medicine. It is a known and expected pattern described in the safety profile.


Q: Can Compensan retard cause changes in weight?

A: Changes in weight are not listed as a common side effect in official documents. However, official warnings describe a serious condition called Adrenal Insufficiency, where the adrenal glands do not work well. Signs of this rare condition may include unusual tiredness, weakness, and weight loss.


Q: Is it possible to have a severe allergic reaction to Compensan retard?

A: Yes, the medicine is contraindicated (must not be used) in patients with a known history of hypersensitivity to morphine. Serious allergic reactions are possible, and symptoms like rash, swelling, and difficulty breathing are considered serious and are listed in regulatory documents as needing urgent medical review.


Q: Can older adults (senior citizens) typically use Compensan retard safely?

A: Official documents state that older adults may be more sensitive to the effects of the medicine and are at an increased risk for respiratory depression. This is noted as the most serious hazard documented. A reduction in dosage may be advisable for older or debilitated patients, and close monitoring is recommended.


Q: Is Compensan retard ever used in children or teenagers?

A: The safety and efficacy of the prolonged-release formulation have not been established in the pediatric population (children). Official documentation states that accidental ingestion of even a single dose by a child who is not opioid-tolerant is an explicitly documented risk for fatal overdose.


Q: What should I do if I miss a scheduled dose of Compensan retard?

A: Instructions in regulatory documents related to a missed dose generally describe skipping the missed dose and returning to the regular schedule for the next dose. These documents typically state that a double dose should not be taken.


Q: Does Compensan retard require any special monitoring or blood tests while being used?

A: Official documents require treatment to be conducted within the context of appropriate medical monitoring. Patients who have severe renal (kidney) or hepatic (liver) impairment may require close monitoring or specific tests, as slower clearance of the substance can occur in these groups.


Q: How long does treatment with Compensan retard usually last?

A: Official guidelines state that the medicine should be used for the shortest duration of time consistent with individual patient treatment goals. When long-term treatment is being discontinued, the dose must always be gradually reduced, as abrupt cessation is prohibited.


Q: Are there long-term health risks associated with using Compensan retard for many years?

A: Yes, prolonged and long-term use is associated with several risks documented in the safety profile. These include the development of tolerance (needing higher doses for the same effect) and physical and psychological dependence. The risk of developing Opioid Use Disorder (OUD) is also documented.


Q: Why do doctors often start patients on a very low dose of Compensan retard?

A: Official instructions advise initiating treatment with a low dose for patients who are not already opioid-tolerant. This precaution is essential because using a higher starting dose in a non-tolerant patient significantly increases the risk of fatal respiratory depression (stopped or shallow breathing).


Q: Has Compensan retard been studied in people with other chronic illnesses?

A: The core research primarily focused on adults who were otherwise clinically stable. Official documents note that there is limited information regarding the use of this medication in patients with co-occurring chronic conditions, meaning the evidence base for these specialized patient groups is not fully established.


Q: Where can I find the official patient information leaflet for Compensan retard?

A: The official patient information, such as the Medication Guide or Patient Information Leaflet, can be found on government websites that regulate drug information. You can search for the active ingredient, Morphine Sulfate, on sites like the FDA, NIH MedlinePlus, or DailyMed.


Q: Why is it important to take this medicine at the same time every day?

A: Taking the medicine at the same time every day is necessary because the prolonged-release tablets are designed to maintain a consistent concentration of the substance in the bloodstream over the entire 12 or 24-hour dosing interval. This consistency is key to ensuring continuous therapeutic effects.


Q: Can people with high blood pressure take Compensan retard?

A: While high blood pressure is not listed as a formal contraindication, official warnings note that this medicine may cause or worsen hypotension (low blood pressure), particularly in patients who are ambulatory. High blood pressure status is a factor that is generally monitored by prescribing physicians.


Q: How is the medicine handled by the body (absorbed and eliminated)?

A: The medicine is absorbed slowly over an extended time due to its prolonged-release design. It is primarily processed by the liver and then eliminated from the body via the kidneys. Slower elimination (clearance) can occur in patients with severe hepatic or renal impairment.


Q: Are there any known interactions between Compensan retard and herbal supplements?

A: Official documents specifically mention that the herbal product St. John's Wort may interact with this medicine. Official guidance emphasizes that the concurrent use of herbal supplements requires careful medical consideration.


Q: Does the medicine lose its effectiveness over time?

A: Yes, prolonged use can lead to the development of tolerance, which is when the body may become accustomed to the medicine. This means that, over time, a patient may require higher doses to achieve the same therapeutic effect.


Q: Can Compensan retard affect sleep patterns?

A: Yes, official documents list somnolence (drowsiness) and sedation as very common adverse reactions. Furthermore, serious adverse events reported include interrupted breathing during sleep, known as sleep apnea, and other mental or mood changes.


Q: Is there a maximum dose of Compensan retard described in official guidelines?

A: Official documents describe the maximum strength available for use (e.g., 100 mg and 200 mg) and advise that the dose should be the lowest effective dosage for the shortest duration consistent with treatment goals. High strengths are strictly reserved for patients who have already established opioid tolerance.


Q: Do official documents mention any mental or mood changes as a side effect?

A: Yes, official documentation lists mood changes as a common adverse reaction. More serious side effects that necessitate urgent review may also involve other mental or mood changes, such as confusion or hallucinations.


Q: How does the drug's purpose relate to the official classification of the medicine?

A: The medicine's official classification as an opioid analgesic means it acts on mu-opioid receptors to modulate signals in the body. This specific action is utilized in its general purpose as a substitution medicine for the maintenance therapy of opioid dependence, providing continuous, stable opioid support to patients.

How should Compensan retard be stored and disposed of?

The storage and disposal of Compensan retard (morphine prolonged-release tablets) must align strictly with official regulatory requirements to maintain product stability and ensure public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store below 30 °C.
Protection Must be protected from light and moisture.
Container Keep in the original container (blister pack and outer carton).
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Compensan retard must be disposed of according to local requirements for pharmaceutical waste.

Disposal by placing the product into household waste or the wastewater system is forbidden to prevent environmental contamination and potential misuse. These tablets should be returned to a designated drug take-back site or pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Compensan retard found in:

A-Z Index: